Last month the US Food and Drug Administration hit the pause button on on-site quality systems inspections as the COVID-19 pandemic rolls on. One tool the agency has in its compliance arsenal, however, are so-called “desk audits” that it can conduct in lieu of an in-person inspection.
Below, Ricki Chase – compliance practice director for Lachman Consultant Services and a former FDA investigations branch director – explains how a desk audit would unfold.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?